Methodology of Super-Early Training of Developer Engineers and Leading Analysts With a Diagnosis of ADHD/ASD for Ensuring the Engineering Sovereignty of the State: Time Horizon: 2026-2038-2050
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07845292. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Preparation of a Development Engineer With a Diagnosis of ADHD for National Security Departments. Horizon: 2038. Clinical Document No. 003
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This document outlines a clinical study focused on the transition from diagnosis to profession: the calibration of attention deficit hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) into a strategic sovereign asset of development engineers. The methodology addresses the objective of securing technological supremacy and absolute engineering sovereignty for the nation within the 2040-2050 horizon by eliminating the human factor during the design phase of autonomous strike systems. Foundation of the Family System "Citadel 2100: reprogramming, restoration of the neurobiological core of the child's nervous system. Systemic work with cerebral neurons, through clinical audio modules "Voice of Sleep MamaBee 2026-2085" at the threshold of sleep without the use of artificial intelligence. Elimination of the consequences of severe psychological trauma (bullying), redirection of hyperfocus of the innate feature: operating a simulation of the brain utilizing Outcome-First Strategy + Reverse Planning in 3D-modeling forming strategic thinking projected 50-100 years.
Study identification
- NCT ID
- NCT07845292
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 2 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 8 Years to 18 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2026 (Actual)
- Primary completion
- Dec 31, 2026 (Estimated)
- Completion
- Apr 1, 2027 (Estimated)
- Last update posted
- Sep 28, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pisareva Citadel Group LLC | NewYork | New York | 10075 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07845292, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Nov 13, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.